XEOMIN® Efficacy | Chronic Sialorrhea

Adults With Chronic Sialorrhea

XEOMIN Patients Had Significant and Sustained Reductions in unstimulated Salivary Flow Rate (uSFR) Over 16 Weeks1,2

Image of chart showing the "Improvements in unstimulated Salivary Flow Rate (uSFR) were sustained over 16 weeks) Pinch to zoom

*P<0.01.
P<0.001 vs placebo.

Sustained Improvements in Global Impression of Change Scale (GICS) Score Over 16 Weeks

Improvments were sustained over 16 weeks in Global Impression of Change Score (GICS) Pinch to zoom

P<0.01.
§P<0.001 vs placebo.
P<0.05.

References

  1. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo–controlled, randomized, double–blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982–e1991.
  2. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.
  3. Data on file. Raleigh, NC: Merz North America, Inc.; 2019.